Login to Your Account

Cytori taps Azaya for potential revenue, nanotech platform

By Michael Fitzhugh
Staff Writer

Thursday, January 19, 2017

The acquisition of two partner-ready nanoparticle cancer candidates developed by Azaya Therapeutics Inc. and an associated nanotech platform could yield potential near-term revenue for Cytori Therapeutics Inc.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription